Abstract LB024: Pharmacokinetics of a novel viscoelastic suspension of trastuzumab biosimilar for high-concentration, low-volume subcutaneous injection
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb024
Abstract: Background: Xeris Pharmaceuticals (Chicago, IL, USA) has developed the proprietary XeriJect® technology, which uses a novel viscoelastic suspension for delivery of high-concentration, low-volume subcutaneous (SC) injections of therapeutic antibodies. Trastuzumab (TmAb) is a monoclonal antibody… read more here.
Keywords: injection; xeriject tmab; herceptin; high concentration ... See more keywords